Ashraf Allam
Founder & CEO
Ashraf Allam
Ashraf Allam has been recently serving as the CEO of the Pharmaceutical Investment Company (PIC) which is fully owned by the Public Investment Fund (PIF). PIF is a global investment powerhouse and one of the largest sovereign wealth funds in the world, with assets of more than $500 billion. The fund is building a world-class, diversified portfolio through investments in attractive, long-term opportunities at the domestic and international levels. In his capacity, Ashraf was fully responsible for creating, providing, and implementing strategic, financial, and operational leadership for the company, working closely with the senior executive team representing both the shareholders and the board of directors.
Ashraf sits on the boards of several other international and regional pharma, biotech, medical devices, diagnostics, and self-medication companies. Prior to joining PIC in early 2021, for more than seven years he was the Regional Vice President of Mundipharma Middle East, Turkey, and Africa region, based in Dubai. Ashraf was responsible for managing the business across the META region and was fully accountable for profit and loss. In addition, he was also a Member of the Global Senior Executive Team of Mundipharma. Mundipharma is a leading research, development, and manufacturing privately held, a multinational pharmaceutical company with annual revenues of ~$4.0 billion
Ashraf sits on the boards of several other international and regional pharma, biotech, medical devices, diagnostics, and self-medication companies. Prior to joining PIC in early 2021, for more than seven years he was the Regional Vice President of Mundipharma Middle East, Turkey, and Africa region, based in Dubai. Ashraf was responsible for managing the business across the META region and was fully accountable for profit and loss. In addition, he was also a Member of the Global Senior Executive Team of Mundipharma. Mundipharma is a leading research, development, and manufacturing privately held, a multinational pharmaceutical company with annual revenues of ~$4.0 billion
Ashraf was the Chairman of the Executive Committee for the Association of American and European research-based manufacturing pharma companies (PhRMA) in the Middle East and Africa. He was elected by other industry leaders of member companies and served in that capacity for several years. In addition, Ashraf was the Chairman of the Board, for the Self-Medication Industry Association for the Middle East and Africa region and also a Board Member of Mecomed, the industry’s association for medical devices and diagnostics.
Before joining Mundipharma in late 2013, Ashraf was appointed by Amgen; one of the world’s largest Biopharmaceuticals companies (Market Cap ~ USD 180 bn) as their Vice President for International Business Development based in Switzerland, in addition to having full profit and loss responsibility for the European markets of Italy, Greece and the Balkans. He was also heading the Corporate Development division focusing on growth, diversification, and globalization of Amgen’s business and was one of the key executives in the Global Strategy and Commercial Development Executive Team. In 2006, Ashraf moved to Dubai to establish Amgen’s operation in the Middle East, Turkey, and Africa region which in less than six years became one of the leading, top-ranked companies in the region.
Before joining Mundipharma in late 2013, Ashraf was appointed by Amgen; one of the world’s largest Biopharmaceuticals companies (Market Cap ~ USD 180 bn) as their Vice President for International Business Development based in Switzerland, in addition to having full profit and loss responsibility for the European markets of Italy, Greece and the Balkans. He was also heading the Corporate Development division focusing on growth, diversification, and globalization of Amgen’s business and was one of the key executives in the Global Strategy and Commercial Development Executive Team. In 2006, Ashraf moved to Dubai to establish Amgen’s operation in the Middle East, Turkey, and Africa region which in less than six years became one of the leading, top-ranked companies in the region.
From 2001 to 2004 he has served at Johnson & Johnson as the Managing Director, responsible for managing the group’s umbrella of diversified medical devices and diagnostics companies based in Cairo.
Prior to J&J, Ashraf worked for Eli Lilly & Company in a variety of general management, commercial, management development, and business development senior roles in the USA, Europe, and the Middle East. He was also the Director of Global Economic Affairs and Pricing based in Indiana, USA, having previously been based in Geneva, Switzerland as the Head of Area Sales and Marketing Operations for Central Eastern Europe, Middle East & Africa.
Prior to J&J, Ashraf worked for Eli Lilly & Company in a variety of general management, commercial, management development, and business development senior roles in the USA, Europe, and the Middle East. He was also the Director of Global Economic Affairs and Pricing based in Indiana, USA, having previously been based in Geneva, Switzerland as the Head of Area Sales and Marketing Operations for Central Eastern Europe, Middle East & Africa.